Drugs / 68Ga-RM26
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06412952 | Oct 2022 → May 2024 | glioma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05549024 | Aug 2022 → Dec 2025 overdue | brain neoplasm, breast cancer, prostate cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-RM26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06412952 ↗ |
| Known as | 68Ga-NOTA-RM26 | “This study aimed to firstly evaluate the feasibility of 68Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma...” PMID 39821814 ↗ Jan 2025 |
| Modality | Diagnostic / imaging agent | “an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer” NCT06412952 ↗ |
| Route | Intravenous | “after intravenous administration of 68Ga-RM26-RGD and 68Ga-RM26, respectively.” NCT05549024 ↗ |